β-lactam side-chain cross-reactivity

For an IgE-mediated β-lactam allergy, lists the agents that share the culprit’s R1 side chain (highest cross-reactivity risk) versus structurally distinct options.

Evidence tier: Expert consensus. A structure-based reference, not a substitute for skin testing or graded challenge. Shared side chain = higher risk; distinct side chain ≠ guaranteed tolerance.

Formula / logic

β-lactams that share an R1 side chain carry the highest IgE cross-reactivity; the shared β-lactam core contributes much less. Cefazolin’s side chain is unique. Ceftazidime ↔ aztreonam share an identical side chain.

Interpretation

Use to choose a side-chain-distinct alternative for an allergic patient, and to flag the high-risk pairings (e.g., ceftazidime/aztreonam, amoxicillin/cefadroxil). Confirm tolerance with testing/challenge where indicated.

Evidence & citations

  1. Zagursky RJ, Pichichero ME. Cross-reactivity in β-Lactam Allergy. J Allergy Clin Immunol Pract. 2018;6(1):72-81.e1. PMID 29017833
  2. Romano A, Valluzzi RL, Caruso C, et al. Cross-Reactivity and Tolerability of Cephalosporins in Patients with IgE-Mediated Hypersensitivity to Penicillins. J Allergy Clin Immunol Pract. 2018;6(5):1662-1672. PMID 29408440

Clinician decision support. Verify against the cited source. Not a substitute for clinical judgment. 100% on-device; no patient data is stored or transmitted.